Masimo (MASI) Scheduled to Post Quarterly Earnings on Tuesday

Masimo (NASDAQ:MASI) is set to issue its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.71 per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.43. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The firm had revenue of $548.90 million for the quarter, compared to analyst estimates of $545.69 million. During the same quarter in the prior year, the firm earned $1.32 EPS. The company’s revenue was down 11.0% on a year-over-year basis. On average, analysts expect Masimo to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Masimo Price Performance

Shares of MASI traded up $0.38 during mid-day trading on Tuesday, hitting $136.58. 88,721 shares of the company traded hands, compared to its average volume of 549,429. The company has a current ratio of 2.18, a quick ratio of 1.22 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $7.23 billion, a price-to-earnings ratio of 90.20 and a beta of 0.97. The business has a 50-day moving average of $135.80 and a 200 day moving average of $117.18. Masimo has a one year low of $75.22 and a one year high of $190.82.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Piper Sandler boosted their price target on shares of Masimo from $70.00 to $117.00 and gave the stock a “neutral” rating in a research note on Monday, February 26th. Stifel Nicolaus upgraded shares of Masimo from a “hold” rating to a “buy” rating and increased their price target for the company from $148.00 to $170.00 in a research report on Monday, April 15th. StockNews.com upgraded shares of Masimo from a “sell” rating to a “hold” rating in a report on Friday, March 29th. Jefferies Financial Group reaffirmed a “hold” rating and set a $121.00 price target (up previously from $107.00) on shares of Masimo in a research report on Tuesday, January 30th. Finally, Wells Fargo & Company raised Masimo from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $117.00 to $160.00 in a research note on Monday, March 25th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $137.43.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.